Athersys (NASDAQ:ATHX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Adamis Pharmaceuticals Provides Update On Clinical Study Assessing Tempol For The Treatment Of COVID-19; Says
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today